Compare Enveric Biosciences Inc (ENVB) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Kohl's Corporation — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Kohl's Corporation trades at $18.49 (market cap $2.16B). The key difference: Kohl's Corporation is far larger — about 348.4× Enveric Biosciences Inc's market cap, and Kohl's Corporation pays a 2.63% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | KSS | |
|---|---|---|
Market Cap | $6.20M | $2.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $24.71 |
52-Week Low | $1.27 | $11.72 |
Enterprise Value | $1.30M | $8.26B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Kohl's (KSS) trades at $19.30, up 4.54% in the last session, with a bullish technical signal from moving averages. The stock shows attractive valuation ratios, including a P/E of 8.11 and P/B of 0.54, but faces revenue declines from $16.22B in 2025 to an expected $15.5B in 2026. Recent Q1 2026 earnings beat estimates, and the company appointed a new COO to drive operational improvements.
The outlook is mixed: low valuations and earnings beats offer upside, but persistent sales drops and thin net margins near 1.77% pose risks. Analyst consensus is cautious with a $16.75 price target below the current price, reflecting concerns over competitive pressures and cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
